Investigating how p38gamma MAPK signaling contributes to intestinal cancer development
p38gamma MAPK signaling promotes intestinal tumorigenesis
['FUNDING_R01'] · MEDICAL COLLEGE OF WISCONSIN · NIH-11138437
This study is looking at how a specific protein called p38gamma might influence the growth of colorectal cancer, especially in relation to inflammation, and it aims to find out if blocking this protein can help prevent or treat the disease in mice, which could lead to new treatments for people.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | MEDICAL COLLEGE OF WISCONSIN (nih funded) |
| Locations | 1 site (MILWAUKEE, UNITED STATES) |
| Trial ID | NIH-11138437 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding the role of p38gamma MAPK signaling in the development of colorectal cancer (CRC), which is significantly influenced by inflammation. The study aims to explore how p38gamma affects the phosphorylation of beta-catenin, a key protein involved in cancer growth. By using mouse models, researchers will examine the effects of inhibiting p38gamma on tumor development and inflammation in the intestines. This could lead to new therapeutic strategies targeting this pathway to prevent or treat CRC.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at high risk for colorectal cancer, particularly those with inflammatory bowel diseases or genetic predispositions.
Not a fit: Patients with colorectal cancer who do not have elevated p38gamma signaling or those with advanced-stage cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that specifically target the mechanisms driving colorectal cancer, potentially improving patient outcomes.
How similar studies have performed: Previous research has shown promising results in targeting similar signaling pathways in cancer treatment, indicating potential for success in this approach.
Where this research is happening
MILWAUKEE, UNITED STATES
- MEDICAL COLLEGE OF WISCONSIN — MILWAUKEE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CHEN, GUAN — MEDICAL COLLEGE OF WISCONSIN
- Study coordinator: CHEN, GUAN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.